Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

NCT01362608 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Gouty Arthritis

Interventions

DRUG: Canakinumab, ACZ885
DRUG: Triamcinolone acetonide

Sponsor

Novartis Pharmaceuticals